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Take-home message: WHO has assessed regimen recommendations for isoniazid 
resistant TB to be of very low certainty. The addition of fluoroquinolones to a 12 month 
(isoniazid, rifamycin, ethambutol, short duration pyrazinamide) regimen may be unnecessary 
in certain settings. 
  
 ABSTRACT 
Introduction 2018 World Health Organization (WHO) guidelines for the treatment of 
isoniazid (H) resistant (Hr) tuberculosis recommend a four-drug regimen- rifampicin (R), 
ethambutol (E), pyrazinamide (Z) and levofloxacin (Lfx)- with or without H ([H]RZE-Lfx). This 
is used once Hr is known, such that patients complete six months of Lfx (≥6[H]RZE-6Lfx). 
This cohort study assessed the impact of fluoroquinolones (Fq) on treatment effectiveness, 
accounting for Hr mutations and degree of phenotypic resistance. 
 
Methods This was a retrospective cohort study of 626 Hr tuberculosis patients notified in 
London, 2009-2013. Regimens were described and logistic regression undertaken of the 
association between regimen and negative regimen-specific outcomes (broadly, death due 
to tuberculosis, treatment failure, disease recurrence). 
 
Results Of 594 individuals with regimen information, 330 (55.6%) were treated with (H)RfZE 
(Rf= rifamycins) and 211 (35.5%) with (H)RfZE-Fq. The median overall treatment period was 
11.9 months and median Z duration 2.1 months. In a univariable logistic regression model 
comparing (H)RfZE with and without Fqs, there was no difference in the odds of a negative 
regimen-specific outcome (baseline (H)RfZE, cluster-specific odds ratio 1.05 [95% 
confidence interval 0.60-1.82], p-value 0.87; cluster NHS Trust). Results varied minimally in 
a multivariable model. This odds ratio dropped (0.57 [0.14-2.28]) when Hr genotype was 
included, but this analysis lacked power (p=0.42). 
  
Conclusions In a high-income setting, we found a 12 month (H)RfZE regimen with a short Z 
duration to be similarly effective for Hr TB with or without a Fq. This regimen may result in 
fewer adverse events than the WHO recommendations. 
  
 INTRODUCTION 
Isoniazid (H) is a key drug used in the treatment of both tuberculosis disease (TB) and latent 
TB infections (LTBI). Research into H resistant (Hr) TB has been neglected in favour of 
studies of simultaneous Hr and rifampicin (R) resistance (Rr) i.e. multidrug resistance 
(MDR).[1] Globally, 7.1% of new incident TB patients between 2003 and 2017 had Hr 
disease without associated Rr (henceforth known as ‘Hr TB’) and 7.9% of previously treated 
patients.[2] The distribution of Hr TB varies substantially by country.[1, 3]  
 
Hr has been associated with poor treatment outcomes, the need to tailor treatment 
regimens, and the development of additional drug resistance during treatment.[1] A meta-
analysis of randomised controlled trial (RCT) data, controlling for regimen, demonstrated that 
incidence rates of treatment failure were 10.9 times higher in Hr TB versus drug sensitive 
disease (95% confidence interval {CI} [5.9-20]).[4] In the same study, relapse rates in Hr TB 
were 1.8 fold higher [1.2-2.6], and acquired drug resistance 5.1 times higher [2.3-11.0]. 
 
Given these concerns, policymakers have issued specific treatment guidance for Hr TB. In 
2018 the World Health Organization (WHO) conditionally recommended a regimen of R, 
ethambutol (E), pyrazinamide (Z) and levofloxacin (Lfx) with or without H ([H]RZE-Lfx), to be 
initiated once Hr is confirmed.[5] If treatment starts before Hr is known, it is continued until 
Lfx is used for six months, even if the duration of the other drugs is therefore longer 
(≥6[H]RZE-6Lfx). In the absence of rapid molecular testing for Hr, overall treatment duration 
is thus seven and a half to nine months, depending upon whether liquid or solid culture is 
used.[6] WHO assessed the evidence underlying this regimen to be of very low certainty.[5] 
Within the UK, the National Institute for Health and Care Excellence (NICE) recommends a 
nine month regimen of two months of RZE, followed by seven months of RE.[7] This can be 
extended to 12 months’ duration (10-month continuation phase), if disease is extensive. The 
American Thoracic Society is currently revising its guidance.[8] In 2003, they recommended 
a six-month regimen of RZE, plus a fluoroquinolone [Fq] for extensive disease.[9] All bodies 
acknowledge the need for future studies to optimise regimens e.g. to determine the 
implications of the resistance-causing Hr mutation(s). 
 
In light of the 2018 WHO recommendations, we undertook a retrospective cohort study to 
identify the treatment regimens currently being used for Hr TB in a high-income setting with 
universal healthcare (London, UK). We assessed the importance of including Fqs during 
treatment, accounting for baseline Hr phenotype and genotype. 
 
 
METHODS 
Study population 
We included all patients aged 18 and over notified in England (as a statutory requirement) to 
Public Health England (PHE)’s Enhanced TB Surveillance system (ETS) between 1st 
January 2009 and 31st December 2013 with disease caused by phenotypically Hr 
Mycobacterium tuberculosis. Baseline demographic and basic clinical and microbiological 
data were available from PHE. Individuals notified in London formed the retrospective 
cohort; additional data collection for these individuals is described below.  
 
Treatment regimens 
Detailed regimen, adherence and regimen-specific outcome information was gathered from 
clinical notes at the last hospital to treat the patient recorded by PHE (Supplementary File 1).  
 
Regimens were described and categorised. The rifamycins (Rf) R and rifabutin (Rb) were 
grouped together, as were the injectables, Fqs other than moxifloxacin (M), and the 
previously named group 4/5 drugs.[10, 11] A binary regimen variable was created of RfZE 
regimens in the presence or absence of H with or without an additional Fq: (H)RZE versus 
 (H)RZE-Fq/M. If additional drugs were also included, the regimen was not counted within the 
binary variable. 
 
The presence of high-dose H within the regimen was documented, as was whether Rf, Z or 
E were dosed thrice weekly (as opposed to more frequently). The length of time a patient 
was treated before the regimen was adapted to account for Hr (which was dependent on the 
duration of drug sensitivity testing; DST) was grouped 0-<2, 2-<6 and ≥6 months.  
 
Genotyping and phenotyping 
Phenotypic DSTs for first line drugs were conducted on baseline samples. DSTs for second 
line drugs were conducted if resistance to R or two or more other first line drugs (but not H 
alone, although this could be requested) was detected. These results were recorded within 
ETS. Patients were grouped according to the baseline drug resistance pattern of their 
disease. 
 
The degree of phenotypic resistance to H was extracted from the National Mycobacterial 
Reference Service (NMRS) South system (Supplementary File 1).  
 
Whole genome sequencing (WGS) to detect resistance mutations was undertaken for a 
subset of patients among those notified 2012-13 using an Illumina HiSeq at the PHE central 
sequencing unit.[12]  
 
Other exposure variables 
Age, sex, being born in the UK, ethnic group, social risk factors (homelessness, problematic 
drug use, problematic alcohol use, and imprisonment), previous diagnosis of TB and 
inpatient information came from ETS. Decisions surrounding the grouping of these variables 
are documented in Supplementary File 1. 
 
An outbreak of Hr TB has been present in (mainly north) London since 1995.[13, 14] Due to 
awareness of this outbreak among clinicians, patients with epidemiological risk factors 
consistent with the outbreak- in which non-adherence was common and treatment outcomes 
poor- may have been treated differently from other patients. 
 
An additional variable documented if a patient had issues adhering to treatment, according 
to their clinical notes (Supplementary File 1). 
 
Outcomes 
A patient’s treatment period for Hr TB is made up of up to three components- the regimen 
used prior to Hr being known, the regimen used once Hr is known, and (potentially) a further 
regimen or regimens if the Hr regimen is insufficiently effective. Overall treatment outcomes 
(available in ETS) capture this entire period. Regimen-specific outcomes, taken from clinical 
notes, document the effectiveness of the Hr regimen and thus capture only the first two 
components (Table 1). For the regression model, the neutral and positive groups were 
merged to create a binary outcome. 
  
 Table 1: Classification of regimen-specific outcomes 
Regimen-specific outcomes (extracted from clinical notes) presented in detail. The first outcome 
arising per patient was documented, unless a negative outcome occurred after one that is neutral. 
MIRU-VNTR- Mycobacterial Interspersed Repetitive Unit-Variable Number of Tandem Repeats, PHE- 
Public Health England, TB- tuberculosis 
Regimen-specific 
outcome 
Components Comments 
Negative Treatment completed, followed by 
recurrence. Outcome missing, but 
recurrence. Neutral outcome, followed 
by recurrence. 
Recurrence of disease 12 months or more 
after notification. Recurrences documented 
until the end of 2015 (the most recent 
available data at the time of analysis). If 
disease recurred after the end of treatment 
at any time and the patient re-presented to 
the same hospital this also classified as a 
negative outcome. 
Died due to TB or death TB-associated 
two weeks or more after starting 
treatment 
Death before two week threshold 
considered to be too early to be influenced 
by the treatment.[15]  
Treatment stopped early or regimen 
changed due to worsening/not 
improving, treatment failure, adverse 
events, or the development of 
additional drug resistance 
Length extended, antibiotics 
added/removed, frequency altered, dose 
altered, treatment stopped. 
Additional drug resistance developed 
during treatment 
To any drug. 
Neutral Died from TB or death TB-associated 
within two weeks of starting treatment 
Death before two week threshold 
considered to be too early to be influenced 
by the treatment.[15]  
Died from non-TB related causes, or 
cause unknown 
 
Treatment stopped early or regimen 
changed due to non-adherence, loss to 
follow up, patient choosing to cease 
their medication, pregnancy, or 
comorbidities 
 
Patient transferred to another hospital 
during their treatment 
No further documentation. Transfer before 
any negative outcomes occurred. 
Positive Treatment completed as initially 
prescribed (once Hr known). Treatment 
completed, no recurrence 
 
 
Analysis 
Data were cleaned in Microsoft Excel and analysed in Stata 15.  
 
The characteristics of the London cohort were assessed. Descriptive analyses of the 
regimens used were undertaken, followed by regression analyses. Initially, individuals with 
additional phenotypic drug resistance identified in baseline samples taken were excluded 
from the regression models, unless resistance was to streptomycin (S).  This was because S 
is not routinely used in the treatment of drug sensitive or MDR TB in the UK.[7, 16] Random 
effects univariable logistic models were built to examine the impact of different factors on the 
likelihood of negative regimen-specific outcomes, with a random effect included on NHS 
Trust to adjust for clustering. 
 
A multivariable logistic model was then built, using the binary regimen categorisation as the 
main exposure and including a random effect on NHS Trust. Details of confounder selection, 
etc. are presented in Supplementary File 1. 
 
Sensitivity and extended analyses 
Four additional logistic regression models were run. The first included Hr genotyping results. 
Next, adherence was substituted for thrice weekly dosing. The third included all patients, 
regardless of whether they were resistant to drugs in addition to H (and S). The fourth was a 
 post hoc model adjusting for factors associated with the use of Fqs. 
 
Ethical permissions 
PHE is legislated by the National Information Governance Board to hold and analyse 
surveillance data for public health purposes under Section 251 of the NHS Act 2006. This 
retrospective cohort study was approved by the London Camberwell St Giles Research 
Ethics Committee (16/LO/1269) and given permission to undertake data extraction without 
consent also under Section 251 (Confidentiality Advisory Group reference 16/CAG/0092). 
 
 
RESULTS 
Patient population 
1,228 individuals with Hr TB were notified in England between 2009 and 2013 (Figure 1). Of 
these, 626 (51.0%) were notified by 31 hospitals (Supplementary File 2) in London (19 NHS 
Trusts). One hospital had only a single patient and was not approached for local approvals. 
The baseline characteristics of the London cohort are described in Table 2. 
  
 Table 2: Baseline characteristics of study participants 
Demographic and clinical baseline characteristics of the 626 individuals in the London cohort. Col.- 
column, CNS- central nervous system, No.- number, TB- tuberculosis, ±- with or without, -ve- 
negative, +ve- positive 
Exposure variables 
London 
No. Col. % 
Overall   626 100 
Year     
 2009 137 21.9 
 2010 118 18.8 
 2011 141 22.5 
 2012 125 20.0 
 2013 105 16.8 
 Missing 0 0.0 
Sex     
 Male 380 60.7 
 Female 246 39.3 
 Missing 0 0.0 
Age (years)   
 18-37 358 57.2 
 38-57 199 31.8 
 58-77 62 9.9 
 ≥78 7 1.1 
 Missing 0 0.0 
UK born     
 No 497 79.4 
 Yes 121 19.3 
 Missing 8 1.3 
Ethnic group   
 White 97 15.5 
 Black African 125 20.0 
 Black Other 45 7.2 
 Indian subcontinent 270 43.1 
 Other 85 13.6 
 Missing 4 0.6 
Social risk factors   
 No or unknown 510 81.5 
 One or more ever 37 5.9 
 One or more current 79 12.6 
Previous TB diagnosis   
 No 575 91.9 
 Yes 20 3.2 
 Missing 31 5.0 
Inpatient     
 No 422 67.4 
 Yes 190 30.4 
 Missing 14 2.2 
Site of disease   
 Pulmonary ± extrapulmonary, smear +ve 194 31.0 
 Pulmonary ± extrapulmonary, smear –ve 159 25.4 
 Meningeal TB or other CNS involvement 24 3.8 
 Other extrapulmonary 249 39.8 
 Missing 0 0.0 
Part of outbreak   
 No 501 80.0 
 Yes 65 10.4 
 Missing 60 9.6 
Any additional drug resistance   
 No 453 72.4 
  Yes 173 27.6 
 
Phenotypic testing for non-H drug resistance revealed that 173/626 (27.6%) patients within 
the London cohort had additional drug resistance at baseline (Supplementary File 3). The 
most common resistance was towards S (139/626 [22.2%]). 
 
 The majority of samples were documented in the NMRS system as highly Hr at baseline 
(495/626; 79.1%). Three (0.5%) displayed borderline results, one was listed as drug 
sensitive (0.2%) and 35 (5.6%) were present in the system but did not have their Hr levels 
logged. 47 individuals could not be found within NMRS, but were recorded as Hr within ETS. 
 
Regimen-specific outcomes 
Regimen-specific outcomes were available for 592/626 patients (94.6%; Table 3). 97 
(16.4%) had a negative outcome. 
 
Table 3: Regimen-specific outcomes and availability of regimen data 
Regimen-specific outcomes and treatment regimen availability for the 592/626 (94.6%) of individuals 
with an outcome recorded in the London cohort. E- ethambutol, R- rifampicin, TB- tuberculosis 
Outcome Negative Neutral Positive 
Frequency of outcome 
(% out of 592) 
97 (16.4) 87 (14.7) 408 (68.9) 
Details of outcome  3 recurrences after treatment 
was completed  
 2 recurrences after an 
otherwise neutral or missing 
outcome 
 3 patients developed additional 
drug resistance (two to R and 
one to clarithromycin; 
additionally one patient 
developed resistance to E and 
one R, but this was pre-dated 
by other negative outcomes) 
 1 patient stopped treatment for 
negative reasons 
 7 patients had the length of 
their treatment extended for 
negative reasons 
 78 treatment regimen changes 
by other means for negative 
reasons 
 3 deaths from TB more than 
two weeks after treatment 
started 
  
Number with regimen data 
(column %) 
95 (97.9) 79 (90.8) 408 (100.0) 
Details of regimen data 
  
 374 with regimen 
data for the full 
duration of 
treatment 
 7 partial 
uncertainties 
surrounding the 
drugs present in 
the regimen 
 27 some date 
information 
missing 
 
Relationship between treatment regimens and regimen-specific outcomes 
Of the 626 patients, 582 (93.0%) had both a regimen-specific outcome recorded and 
treatment information. Of these, 538 (92.4%) were not resistant to drugs in addition to H, 
apart from S, and 84 had a negative regimen-specific outcome (three of which were 
recurrences). 498/538 (92.6%) were treated with (H)RfZE or (H)RfZE-Fq/M (Table 4). For a 
more detailed description of the treatment regimens, see Supplementary File 4. 
  
 Table 4: Univariable logistic regression of treatment regimen and associated factors 
as predictors of negative outcomes 
Univariable logistic regression of treatment regimen and associated factors as predictors of negative 
regimen-specific outcomes. Included patients were notified in London, had regimen-specific outcome 
and regimen information, and their disease was without additional drug resistance, unless to 
streptomycin. Each model contains the patients without missing data. CI- confidence interval, Col.- 
column, E- ethambutol, Fq- fluoroquinolones, H- isoniazid, Hr- isoniazid resistance, No.- number, m- 
months, M- moxifloxacin, OR- odds ratio, p- p-value, Rf- rifamycin, Z- pyrazinamide 
Exposure variables London Negative outcome 
No. Col. % No. Row % OR [95% CI], p-value 
Overall 538 100 84 15.6 - 
Regimen       
 (H)RfZE 306 56.9 46 15.0 p=0.93 
 (H)RfZE-Fq/M 192 35.7 30 15.6 1.02 [0.59-1.77] 
 Missing 40 7.4 8 20.0  
Thrice weekly dosing         
 More frequent 464 86.2 66 14.2 p=0.15 
 Thrice weekly 53 9.9 12 22.6 1.81 [0.83-3.94] 
 Missing 21 3.9 6 28.6  
Time before HR known         
 0-<2m 325 60.4 56 17.2 p=0.27 
 2-<6m 159 29.6 18 11.3 0.62 [0.34-1.13] 
 ≥6m 10 1.9 2 20.0 1.11 [0.22-5.66] 
 Missing 44 8.2 8 18.2  
Phenotype         
 Highly resistant 442 82.2 69 15.6 p=0.73 
 Resistant 36 6.7 5 13.9 0.88 [0.32-2.39] 
 Borderline, sensitive or results not logged 29 5.4 6 20.7 1.46 [0.55-3.88] 
 Missing 31 5.8 4 12.9  
Adherence issues or treatment gaps         
 No or unknown 425 79.0 64 15.1 p=0.29 
 Not severe or of unknown severity 56 10.4 13 23.2 1.62 [0.80-3.28] 
  Severe 57 10.6 7 12.3 0.72 [0.30-1.73] 
 
Differences in the odds of a negative regimen-specific outcome were not detected between 
patients treated with (H)RfZE (baseline) and (H)RfZE-Fq/M (cluster-specific odds ratio [OR] 
1.02 95% CI [0.59-1.77], p-value 0.93; Table 4). None of the other treatment regimens or 
associated factors were found to be associated with the odds of negative outcomes (Table 4, 
Supplementary File 5). We observed more negative outcomes with the use of thrice weekly 
dosing versus more frequent dosing (OR 1.81 [0.83-3.94]), but this may have been a chance 
finding (p=0.15). 
 
Seven exposure variables/confounders were included in the multivariable model regimen: 
thrice weekly dosing, Hr phenotype, sex, age (linear variable), ethnic group and previous TB 
diagnosis. Evidence for effect modification was not found. In the final multivariable model of 
435 patients (Table 5), there was no discernible difference in the odds of a negative outcome 
between the two regimens (0.99 [0.53-1.85], 0.97). The association between thrice weekly 
dosing and negative outcomes was slightly strengthened in terms of the effect estimate (2.34 
[0.90-6.09]), although the association observed could still have been due to chance 
(p=0.09). 
  
 Table 5: Multivariable logistic regression of treatment regimen as a predictor of 
negative outcomes 
Multivariable logistic regression of treatment regimen as a predictor of negative regimen-specific 
outcomes in patients without additional drug resistance, unless to streptomycin, adjusted for all 
variables in the table. Model contains 435 patients. CI- confidence interval, E- ethambutol, Fq- 
fluoroquinolones, H- isoniazid, m- months, M- moxifloxacin, OR- odds ratio, p- p-value, Rf- rifamycin, 
TB- tuberculosis, Z- pyrazinamide 
Exposure variables OR [95% CI), p-value 
Regimen    
 [H)RfZE p=0.97 
 [H)RfZE-Fq/M 0.99 [0.53-1.85] 
Thrice weekly dosing  
 More frequent p=0.09 
 Thrice weekly 2.34 [0.90-6.09] 
Phenotype    
 Highly resistant p=0.66 
 Resistant 0.64 [0.17-2.43] 
 Borderline, sensitive or results not logged 1.40 [0.45-4.31] 
 Missing  
Sex    
 Male p=0.02 
 Female 2.05 [1.13-3.71] 
Age (years)   
 18-37 p=0.46 
 Per 20 year increase 1.18 [0.75-1.86] 
Ethnic group  
 White p=0.15 
 Black African 0.42 [0.15-1.18] 
 Black Other 0.33 [0.08-1.39] 
 Indian subcontinent 0.58 [0.23-1.45] 
 Other 1.10 [0.42-2.92] 
Previous TB diagnosis  
 No p=0.13 
  Yes 3.12 [0.75-12.91] 
 
Impact of genotype and other sensitivity analyses 
The most common Hr genotypes observed were fabG1 C-15T (87/171, 50.9%) and katG 
S315T (75/171, 43.9%; Supplementary File 6). For 10/171 (5.8%) strains, sequencing either 
failed, no resistance mutations were detected, or it was not known whether the single 
nucleotide polymorphisms (SNPs) found generate drug resistance.  
 
In a univariable model, no difference was seen in the likelihood of a negative treatment 
outcome between the katG S315T/N genotypes and a fabG1 C-15T baseline (1.17 [0.42-
3.31], 0.76). In a multivariable model, evidence for effect modification by genotype was not 
detected. Genotype was not independently associated with the outcome (Supplementary 
File 7). In this model, there was a suggestion that the odds of a negative regimen-specific 
outcome were reduced for (H)RfZE-Fq/M versus (H)RfZE (0.57 [0.14-2.28]), but we were 
under-powered for this analysis (p=0.42). 
 
Inclusion of other potential confounder sets in the multivariable model did not impact on our 
findings (Supplementary File 8). 
 
 
DISCUSSION 
In this analysis of Hr TB patients notified by London hospitals between 2009 and 2013, 
16.4% of individuals had a negative outcome. (H)RfZE and (H)RfZE-Fq/M regimens were 
taken by 92.6% of individuals without additional drug resistance (apart from to S) and with 
both regimen and regimen-specific outcome data. Among these patients, we found no 
discernible difference in the odds of a negative regimen-specific outcome between (H)RfZE 
and (H)RfZE-Fq/M regimens. Examining individuals with a positive treatment outcome, the 
 overall duration of treatment was generally 12 months, with Z durations of two months in the 
initiation phase. After adjustment for Hr genotype, the likelihood of a negative outcome was 
found to be lower among individuals treated with (H)RfZE-Fq/M, but this analysis was under-
powered. 
 
Our findings sit in the context of preceding work on the relative efficacy and effectiveness of 
different regimens for Hr TB, including four meta-analyses.[17-20] Fregonese et al.’s 
individual-level patient meta-analysis, the foundation of the 2018 WHO guidelines, showed a 
value for including a Fq in continuous (H)RZE regimens, and suggested equivalence 
between six versus eight to nine months of (H)RZE.[17] The WHO acknowledge that overall 
treatment length findings may be subject to confounding by indication, due to patients with 
more complex sites of disease receiving longer regimens.[5] 
 
Notably, global RCT evidence for the effectiveness of Fqs in non-MDR TB derive solely from 
the Rifaquin trial, as ReMox did not demonstrate non-inferiority when H was replaced with M 
for non-MDR TB.[21, 22] When considering the choice of Fq, although WHO recommends 
the use of Lfx, M was generally used in our study. Within Fregonese et al., roughly equal 
numbers of studies used these two drugs, which were not directly compared. Comparative 
data are, however, available from a MDR TB trial (no difference in treatment outcomes when 
comparing the two drugs; fewer adverse events for M),[23] and rabbit and mouse models (M 
broadly superior over Lfx).[24, 25] Lfx doses in such studies may, however, have been too 
low.[26, 27] Further RCTs are required. 
 
The above meta-analyses were unable to thoroughly consider the role of Hr genotype and 
phenotype in treatment decisions; the evidence from previous observational studies is 
unclear.[1, 28] Where adjustment for genotype in observational studies has been 
undertaken, it was largely for inhA and katG. In our cohort, with a very high prevalence of 
fabG1 in addition to katG mutations, we find an indication that the Hr genotype is influential. 
fabG1 is part of the inhA operon and is involved in fatty acid synthesis; SNPs within the gene 
are known to confer Hr.[29, 30]  
 
The evidence currently underpinning global treatment guidelines for Hr TB is limited. Our 
study adds to this discussion, including consideration of the effect of resistance phenotype 
and genotype on the regimen-outcomes relationship. Importantly, in our core analysis, 192 
patients received a Fq in addition to (H)RfZE, which provides substantial new evidence to 
that presented by Fregonese et al., whose analysis of treatment success included 251 
patients receiving a Fq.[17] Our findings did not differ when site of disease was adjusted for 
as a confounder (including meningeal TB or other CNS involvement; data not shown) and 
when patients with additional drug resistance were included. 
 
Within this study actual, rather than intended, treatment durations were captured, which 
prevented us from undertaking analyses of the impact of overall or drug-specific durations. 
Importantly, however, when considering nine versus 12 months of treatment the majority of 
negative outcomes occurred before nine months and the number of relapses was small, with 
two of the three occurring after more than 15 months of treatment. Thus our data may 
indicate the potential to shorten treatment to nine months in our setting. Some patient notes 
could not be accessed as patients had died. This was unlikely to have been of a magnitude 
sufficient to bias our findings. We did not differentiate between recurrence due to relapse 
versus reinfection, and thus may have over-estimated the number of negative outcomes 
(non-differential misclassification). Gaps in phenotypic data arose due to a) missing records 
within NMRS from a specific period and reference laboratory, and b) incomplete data entry 
into NMRS from the reference laboratory (cross-tabulations against patient characteristics 
did not indicate that this particularly affected any specific patient groups). The phenotypic 
and genotypic Hr patterns documented summarise that of the overall bacterial population; 
the presence of minor strains will not have been captured. Our findings about thrice weekly 
 dosing may represent the use of such a dosing pattern specifically among patients where 
directed observation of treatment was deemed necessary. HIV status, a potential 
confounder, was not obtainable during data collection. 
 
Despite these limitations, there are important ramifications for our findings both nationally 
and internationally. We document a drug combination that differs from that recommended 
(with very low certainty) by the WHO,[5] which may be as effective. We note that, if the 
overall duration of treatment is long enough (12 months), a Fq may not be necessary in 
certain settings, even with relatively short durations (median two months in the initiation 
phase) of Z. Notably, in settings where DST occurs via phenotyping from cultures, the WHO 
regimen ≥6[H]RZE-6Lfx is likely to have total duration of seven and a half to nine months, 
when time to result is considered. This also affects the longer regimen in their six versus 
eight to nine month duration comparison; the latter translates to nine and a half to 12 
months. By comparison, in settings undertaking rapid genotyping directly from patient 
samples, the WHO regimen duration would be six months and the average duration 
documented here approximately 10 months. 
  
Global regimen choices will depend upon the trade-off between patient desire for regimens 
of minimal length, adherence concerns, adverse events, ease of administration, and cost. 
Costs are raised if fixed dose combination pills cannot be used and Fqs are added in. When 
it comes to comparing the likelihood of adverse events, the trade-off would be between a 
longer duration of E but shorter duration of Z in our predominantly used regimen, versus 
continued Z and the addition of LfX, as per the WHO recommendations. Each of these drugs 
has its own distinct adverse event profile.[23, 31]  
 
Fq DST results are important when deciding on Fq use within a Hr regimen. Only 48 
individuals in the London cohort had their baseline samples tested for resistance to M.  In 
2018 PHE rolled-out prospective WGS to provide routine resistance predictions and 
mutation identification, thus improving the rapidity of DST and coverage of second line 
testing. New molecular Hr tests can also aid rapidity, as the use of WGS still depends on 
culture.[32]  
 
Within the limitations of an observational study, where the use of Fqs was not randomised, 
we find in a high-income setting with comprehensive patient management, a 12 month 
(H)RfZE regimen with a short Z duration to be similarly effective for Hr TB, with or without a 
Fq. Hr genotype may influence these findings. In the absence of Fqs and long durations of Z, 
this regimen may have fewer adverse events than the WHO recommended ≥6[H]RZE-6Lfx. 
RCTs analyses should be undertaken to provide stronger global recommendations.  
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FIGURE LEGENDS 
 
 
Figure 1: Flow chart of participants  
Hr- isoniazid resistant, PHE- Public Health England, TB- tuberculosis 
 
  
 Supplementary File 1: Additional methods 
 
REGIMEN AND ADHERENCE DATA EXTRACTION 
A standardised form was used for data extraction from clinical notes. Data collection was 
completed on 15th December 2017. Drug names, start and end dates, dosing, and frequency 
of administration were collected, as well as any notation in a patient’s notes by hospital staff 
of issues with adherence (including dates and the number of doses missed, where possible) 
and patient outcomes. Use of directly observed therapy (DOT) was also recorded. In the UK 
DOT is generally provided to patients deemed to be at especial risk of non-adherence, either 
at the start of treatment or during treatment, although some hospitals routinely DOT all 
patients for the first two months. It frequently is used with thrice weekly dosing. Duration 
calculations omitted gaps in treatment. 
 
PHENOTYPIC LEVELS OF DRUG RESISTANCE 
607/626 (97.0%) of samples were phenotyped within a single reference laboratory, one 
sample at a second site external to London, and the rest within a second London reference 
laboratory. Drug sensitivity tests were performed to standard operating procedures across all 
sites.[1, 2] Resistance ratios were used to determine which strains were resistant to H and 
which highly resistant. The growth of test strains across three test slopes is compared to wild 
type strains and so, depending on the controls, the cut-off concentration threshold can vary. 
High levels of resistance are usually called when there is growth on all three slopes, 
including at the highest concentration (0.2mg/l H). Resistant, but not highly resistant, strains 
usually grown on two of the three slopes, up to 0.1mg/l H.  
 
OTHER EXPOSURE VARIABLES 
Site of disease was combined with smear status to generate a single variable with four 
strata: pulmonary with or without extrapulmonary site(s) smear positive, pulmonary with or 
without extrapulmonary site(s) smear negative or smear status missing, meningeal or other 
central nervous system (CNS) sites, other extrapulmonary sites only. The separate 
meningeal/CNS grouping was due to the difficulty of treating TB in these sites. 
 
The presence of one or more social risk factors (homelessness, problematic drug use, 
problematic alcohol use, and imprisonment) and whether or not they were a current risk- was 
coded into a single variable. 
 
‘Severe’ non-adherence to treatment was classed as treatment gaps of two months or more, 
or any period of taking less than 80% of prescribed doses. 
 
MODEL BUILDING 
Our knowledge of the literature and previous studies was used to decide on the a priori 
confounders age, sex, phenotype, thrice weekly dosing and adherence. Additional potential 
confounders were then identified through causal frameworks.[3] The model-building process 
to generate the final multivariable model has been described before.[4, 5] Briefly, we started 
with a model containing all a priori and potential confounders and undertook a step-by-step 
backwards deletion strategy that sequentially removed potential confounders that were not 
determined to fulfil the three rules of confounding, whilst retaining the a priori confounders  A 
priori it was decided that model fit using linear and categorical variables for age, year and 
time before Hr was known would be compared in the model containing the final covariate 
set. Subsequently, thrice weekly dosing, adherence, Hr phenotype, and Hr genotype were 
assessed for effect modification within this model. All p-values quoted are from likelihood 
ratio tests. We undertook a complete case analysis. 
 
Thrice weekly dosing and adherence were collinear, thus only thrice weekly dosing was 
included in the baseline model. 
 
 REFERENCES 
1. Collins CH, Grange JM, Yates MD. Tuberculosis Bacteriology: Organization and 
Practice. 2nd edition ed: CRC Press; 1997. 
2. Parte A, Whitman WB, Goodfellow M, et al. Bergey's Manual of Systematic 
Bacteriology: Volume 5: The Actinobacteria. 2nd edition ed: Springer; 2012. 
3. Victora CG, Huttly SR, Fuchs SC, et al. The role of conceptual frameworks in 
epidemiological analysis: a hierarchical approach. Int J Epidemiol. 1997;26(1):224-7. 
4. Greenland S, Pearce N. Statistical foundations for model-based adjustments. Annu 
Rev Public Health. 2015;36:89-108. 
5. Stagg HR, Abubakar I, Brown J, et al. Towards better guidance on caseload 
thresholds to promote positive tuberculosis treatment outcomes: a cohort study. BMC Med. 
2016;14:52. 
 
 
  
 Supplementary File 2: List of hospitals contributing data 
The authors wish to endorse the following London, UK hospitals as data contributors for this 
study:  
 Central Middlesex Hospital 
 Charing Cross Hospital 
 Chelsea and Westminster Hospital 
 Croydon University Hospital 
 Ealing Hospital 
 Edgware Hospital 
 Hammersmith Hospital 
 Hillingdon Hospital 
 Homerton Hospital 
 King George’s Hospital 
 King's College Hospital 
 Kingston Hospital 
 London Chest Hospital (now closed) 
 Mile End Hospital 
 Newham General Hospital 
 North Middlesex University Hospital 
 Northwick Park Hospital 
 Princess Royal University Hospital 
 Queen Elizabeth Hospital 
 Queen's Hospital (Romford) 
 Royal Free Hospital 
 St. George's Hospital (Tooting) 
 St. Helier Hospital 
 St. Mary's Hospital 
 St. Thomas' Hospital 
 University College Hospital 
 University Hospital Lewisham 
 West Middlesex University Hospital 
 Whipps Cross University Hospital 
 Whittington Hospital 
 
 
  
 Supplementary File 3: Additional drug resistance in the study population 
DST results at baseline. Missingness documents that a sample was not tested against a particular 
drug. Col.- column, DST- drug sensitivity testing, No.- number 
Exposure variables 
England London 
No. Col. % No. Col. % 
Overall   1,228 100 626 100 
Ethambutol     
 Sensitive 1,201 97.8 611 97.6 
 Resistant 23 1.9 15 2.4 
 Missing 4 0.3 0 0.0 
Pyrazinamide     
 Sensitive 1,210 98.5 616 98.4 
 Resistant 13 1.1 9 1.4 
 Missing 5 0.4 1 0.2 
Streptomycin     
 Sensitive 638 52.0 422 67.4 
 Resistant 294 23.9 139 22.2 
 Missing 296 24.1 65 10.4 
Amikacin       
 Sensitive 111 9.0 55 8.8 
 Resistant 0 0.0 0 0.0 
 Missing 1,117 91.0 571 91.2 
Kanamycin     
 Sensitive 89 7.2 37 5.9 
 Resistant 0 0.0 0 0.0 
 Missing 1,139 92.8 589 94.1 
Capreomycin     
 Sensitive 108 8.8 54 8.6 
 Resistant 2 0.2 1 0.2 
 Missing 1,118 91.0 571 91.2 
Ciprofloxacin     
 Sensitive 339 27.6 19 3.0 
 Resistant 4 0.3 0 0.0 
 Missing 885 72.1 607 97.0 
Ofloxacin     
 Sensitive 101 8.2 47 7.5 
 Resistant 0 0.0 0 0.0 
 Missing 1,127 91.8 579 92.5 
Moxifloxacin     
 Sensitive 102 8.3 48 7.7 
 Resistant 0 0.0 0 0.0 
 Missing 1,126 91.7 578 92.3 
Azithromycin     
 Sensitive 151 12.3 0 0.0 
 Resistant 1 0.1 0 0.0 
 Missing 1,076 87.6 626 100.0 
Clarithromycin     
 Sensitive 332 27.0 10 1.6 
 Resistant 13 1.1 11 1.8 
 Missing 883 71.9 605 96.6 
Ethionamide     
 Sensitive 68 5.5 32 5.1 
 Resistant 39 3.2 22 3.5 
 Missing 1,121 91.3 572 91.4 
Prothionamide     
 Sensitive 56 4.6 19 3.0 
 Resistant 34 2.8 18 2.9 
 Missing 1,138 92.7 589 94.1 
  
 Supplementary File 3: continued 
Exposure variables 
England London 
No. Col. % No. Col. % 
Cycloserine     
 Sensitive 18 1.5 17 2.7 
 Resistant 1 0.1 1 0.2 
 Missing 1,209 98.5 608 97.1 
Para-aminosalicylic acid     
 Sensitive 9 0.7 4 0.6 
 Resistant 2 0.2 1 0.2 
 Missing 1,217 99.1 621 99.2 
Linezolid       
 Sensitive 69 5.6 31 5.0 
 Resistant 0 0.0 0 0.0 
 Missing 1,159 94.4 595 95.0 
Rifabutin       
 Sensitive 171 13.9 18 2.9 
 Resistant 0 0.0 0 0.0 
  Missing 1,057 86.1 608 97.1 
 
 
  
 Supplementary File 4: Detailed drug and regimen information 
 
Among individuals with a positive regimen-specific outcome 
Detailed regimen duration information could only be analysed for patients with a positive 
treatment outcome, as only these individuals had full documentation of the use of each drug 
(and associated dates) across the entire treatment course. Individuals with other outcomes 
had regimens truncated to the date treatment stopped. Among the 408 individuals with a 
positive outcome, 374 (91.7%) had regimen data for the full duration of treatment. Thus the 
subsequent text describes the regimens used for these 374 patients. 
 
The median overall treatment duration was 11.9 months and interquartile range (IQR) 9.3-
12.1 months. This figure was slightly lower in the presence of Fqs (10.5 months), with a 
similar IQR (9.1-12.0). The median length of time on treatment before Hr was known was 1.8 
months (IQR 1.1-2.2; eight individuals zero day delay) and after resistance was known 9.9 
months (IQR 8.0-10.7). 
 
372/374 individuals (99.5%) received R only, one Rb only, and one both drugs. (Across the 
entire cohort four patients were treated with Rb.) The median duration of Rf usage was 11.9 
months (IQR 9.2 to 12.1). The median duration of E (371 individuals) was 11.8 months (9.1 
to 12.1). These figures were 2.2 months (2.0 to 3.0; usually entirely in the initiation phase) 
for the 368 individuals given Z and 5.5 months (3.9 to 8.7) for the 151 given M. 400mg 
administered daily was the standard M dosage, with a few patients receiving 600mg. Six 
individuals received Fqs other than M (three ofloxacin, two Lfx, one ciprofloxacin), seven 
received group 4/5 drugs (five prothionamide, one prothionamide and cycloserine, one 
clarithromycin), and 11 injectables (eight S, three amikacin). Three of those receiving group 
4/5 drugs and two receiving injectables had meningeal or spinal TB, or other CNS 
involvement. Five of the individuals receiving group 4/5 drugs and five receiving injectables 
had non-S additional drug resistance. Thirty five of the 374 individuals (9.4%) had their Rfs, 
E or Z dosed intermittently; this information was not known for seven patients. There was no 
evidence that any patients were given high dose H. 
 
Thirteen detailed drug regimen categories were generated on the basis of the drugs within 
the regimen and Rf duration (Supplementary File 4 Table 1). The most common regimen 
categories were HRfZE (210/374, 56.1%) and HRfZE-M (119/374, 31.8%) (Supplementary 
File 4 Table 1). For these categories, the most common Rf duration was 9-12 months in both 
cases (116/210, 55.2% and 63/119, 52.9%, respectively). 
 
369 of the 374 patients (98.7%) who completed treatment and had full regimen information 
had a documented date on which Hr was known. The most regimen initiated at this point 
(step-down regimen) was RfE (124/369, 33.6%), followed by RfZE (98, 26.6%) and RfZEM 
(77, 20.9%). 
  
 Table 1: Overall treatment regimens 
Regimens used to treat Hr TB across the entire treatment course for the 374 patients who 
successfully completed treatment and had full regimen information available. Cat.- category, Col.- 
column, E- ethambutol, Fq- fluoroquinolone other than M, H- isoniazid, M-moxifloxacin, m- months, 
No.- number, Rf- rifamycin, +- plus additional drugs, (+)- with or without additional drugs 
Regimen No. Col. % 
Rifamycin 
duration No. Cat. % Additional drugs No. Cat. % 
HRfZE 210 56.1 ≤6m 6 2.9    
   >6-≤9m 18 8.6    
   >9-≤12m 116 55.2    
   >12m 70 33.3    
HRfZE-M 119 31.8 ≤6m 3 2.5    
   >6-≤9m 22 18.5    
   >9-≤12m 63 52.9    
   >12m 31 26.1    
HRfZE-M+ 12 3.2    Injectables 6 50.0 
      Injectables, group 4/5 2 16.7 
      Fqs, group 4/5 2 16.7 
      Group 4/5 2 16.7 
HRfZE-Fq(+) 3 0.8    None 2 66.7 
      Group 4/5 1 33.3 
HRfZE+ 2 0.5    Injectables 2 100.0 
HRfZ-M 3 0.8       
HRfE-M 2 0.5       
HRfE 1 0.3       
RfZE-M 14 3.7       
RfZE(+) 5 1.3    None 4 80.0 
      Injectables 1 20.0 
RfE-M 1 0.3       
RfE-Fq 1 0.3       
RfE 1 0.3             
Total 374 100.0             
 
Use of fluoroquinolones 
In order to ascertain whether the use of Fqs was unevenly distributed across key clinical and 
demographic groups, or whether different durations of Fqs were used in these groups, data 
were further tabulated. The inclusion, but not duration, of Fqs was associated within the 
presence of additional drug resistance and site of disease (Supplementary File 4 Tables 2 
and 3). These two variables were thus included in sensitivity analyses (Supplementary File 
8). 
  
 Supplementary File 4: continued 
 
Table 2: The inclusion of fluoroquinolones in the treatment regimen, by important 
clinical and demographic characteristics 
594 patients had at least some regimen data (Figure 1); 16 of these did not have information on the 
inclusion of fluoroquinolones in their regimen and thus 578 remain to examine the usage of this drug. 
CNS- central nervous system, Fq- fluoroquinolone other than M, M- moxifloxacin, TB- tuberculosis, 
*19 additional people were missing information on dosing frequency, ±- plus or minus, +ve- positive, -
ve- negative 
Exposure variables Total 
Fq/M included 
in regimen 
(row %) 
Age (years)   
 18-37 336 136 (40.5) 
 38-57 179 87 (48.6) 
 58-77 57 27 (47.4) 
 ≥78 6 1 (16.7) 
Site of disease   
 Pulmonary ± extrapulmonary, smear +ve 176 90 (51.1) 
 Pulmonary ± extrapulmonary, smear –ve 147 61 (41.5) 
 Meningeal TB or other CNS involvement 21 14 (66.7) 
 Other extrapulmonary 234 86 (36.8) 
Any additional drug resistance   
 No 534 224 (42.0) 
 Yes 44 27 (61.4) 
Thrice weekly dosing*   
 More frequent 497 209 (42.1) 
 Thrice weekly 62 33 (53.2) 
Adherence issues or treatment gaps   
 No or unknown 451 187 (41.5) 
 Not severe or of unknown severity 69 33 (47.8) 
 Severe 58 31 (53.5) 
 
Table 3: The overall duration of treatment, by important clinical and demographic 
characteristics 
374 patients successfully completed treatment, had full regimen information available, and thus can 
have overall treatment duration calculated (Table 3). Durations quoted in months. CNS- central 
nervous system, IQR- inter-quartile range, TB- tuberculosis, *- seven additional people were missing 
information on dosing frequency, ±- plus or minus, +ve- positive, -ve- negative 
Exposure variables Total 
Overall 
treatment 
duration (IQR) 
Age (years)   
 18-37 225 12.0 (9.3-12.2) 
 38-57 109 11.9 (9.2-12.0) 
 58-77 36 10.9 (9.2-12.1) 
 ≥78 4 12.0 (11.8-12.2) 
Site of disease   
 Pulmonary ± extrapulmonary, smear +ve 108 12.0 (9.5-12.2) 
 Pulmonary ± extrapulmonary, smear –ve 97 11.9 (9.2-12.0) 
 Meningeal TB or other CNS involvement 8 12.3 (11.9-15.2) 
 Other extrapulmonary 161 11.8 (9.2-12.2) 
Any additional drug resistance   
 No 347 11.9 (9.3-12.1) 
 Yes 27 11.9 (9.2-13.0) 
Thrice weekly dosing*   
 More frequent 332 11.9 (9.3-12.1) 
 Thrice weekly 35 11.5 (9.2-12.2) 
Adherence issues or treatment gaps   
 No or unknown 306 11.9 (9.2-12.1) 
 Not severe or of unknown severity 37 12.0 (11.5-13.9) 
 Severe 31 10.6 (9.3-12.6) 
 
  
 Supplementary File 5: Univariable logistic regression of baseline characteristics as a 
predictor of negative outcomes 
Univariable logistic regression of demographic and clinical baseline characteristics as predictors of 
negative regimen-specific outcomes in patients without additional drug resistance, unless to 
streptomycin. Each model contains the patients without missing data. CI- confidence interval, CNS- 
central nervous system, No.- number, OR- odds ratio, p- p-value, TB- tuberculosis, ±- with or without, 
-ve- negative, +ve- positive 
Exposure variables Negative outcome 
No. Row % OR [95% CI], p-value 
Overall 84 100.0 - 
Year 
   
 
2009 16 11.7 p=0.91  
2010 14 11.9 0.84 [0.38-1.89]  
2011 19 13.5 0.99 [0.47-2.09]  
2012 20 16.0 1.22 [0.58-2.58]  
2013 15 14.3 1.12 [0.51-2.47]  
Missing 0 - - 
Sex 
   
 
Male 45 11.8 p=0.12  
Female 39 15.9 1.47 [0.90-2.40]  
Missing 0 - - 
Age (years) 
   
 
18-37 43 12.0 p=0.23  
38-57 32 16.1 1.58 [0.93-2.68]  
58+ 9 14.5 1.40 [0.62-3.19]  
Missing 0 - - 
UK born 
   
 
No 63 12.7 p=0.16  
Yes 20 16.5 1.57 [0.85-2.91]  
Missing 1 12.5 - 
Ethnic group 
   
 
White 15 15.5 p=0.40  
Black African 13 10.4 0.55 [0.23-1.29]  
Black Other 7 15.6 0.87 [0.31-2.45]  
Indian subcontinent 33 12.2 0.63 [0.29-1.34]  
Other 16 18.8 1.08 [0.47-2.49]  
Missing 0 0.0 - 
Social risk factors 
   
 
No or unknown 69 13.5 p=0.91  
One or more ever 6 16.2 1.15 [0.43-3.08]  
One or more current 9 11.4 0.89 [0.40-1.98] 
Previous TB diagnosis 
   
 
No 77 13.4 p=0.10  
Yes 5 25.0 2.82 [0.89-8.94]  
Missing 2 6.5 - 
Inpatient 
   
 
No 55 13.0 p=0.38  
Yes 28 14.7 1.26 [0.75-2.13]  
Missing 1 7.1 - 
Site of disease 
   
 
Pulmonary ± extrapulmonary, smear +ve 30 15.5 1.47 [0.76-2.83]  
Pulmonary ± extrapulmonary, smear –ve 19 11.9 p=0.45  
Meningeal TB or other CNS involvement 5 20.8 2.19 [0.66-7.23]  
Other extrapulmonary 30 12.0 1.10 [0.58-2.10]  
Missing 0 - - 
Part of outbreak 
   
 
No 70 14.0 p=0.85  
Yes 9 13.8 0.92 [0.41-2.10] 
  Missing 5 8.3 - 
 
  
 Supplementary File 6: Isoniazid resistance mutations 
Isoniazid resistance mutations among the 161 strains that underwent successful genotyping and their 
associated degree of phenotypic resistance to isoniazid. No.- number. 
  Total Phenotype   
    Highly resistant Resistant Borderline 
Genotype   No. Row % No. Row % No. Row % 
ahpC_C-72T 1 1 100.0 0 0.0 0 0.0 
fabG1_C-15T 79 63 79.7 10 12.7 6 7.6 
inhA_I194T/fabG1_C-15T 1 1 100.0 0 0.0 0 0.0 
inhA_I21T/fabG1_C-15T 1 1 100.0 0 0.0 0 0.0 
inhA_S94A/fabG1_C-15T 1 1 100.0 0 0.0 0 0.0 
katG_S315T/N 72 72 100.0 0 0.0 0 0.0 
katG_S315T/fabG1_C-15T 5 5 100.0 0 0.0 0 0.0 
katG_S315T/fabG1_G-17T 1 1 100.0 0 0.0 0 0.0 
Total 161 145 90.1 10 6.2 6 3.7 
 
 
 
  
 Supplementary File 7: Multivariable logistic regression of treatment regimen as a 
predictor of negative outcomes- isoniazid resistance genotype included 
Multivariable logistic regression of treatment regimen as a predictor of negative regimen-specific 
outcomes in patients without additional drug resistance, unless to streptomycin, taking into account Hr 
resistance genotype. Model contains 115 patients and adjusted for all variables in the table, in 
addition to sex, age, ethnic group and previous TB treatment. *strata perfectly predicts the outcome, 
CI- confidence interval, E- ethambutol, Fq- fluoroquinolones, H- isoniazid, m- months, M- 
moxifloxacin, OR- odds ratio, p- p-value, R- rifamycin, TB- tuberculosis, Z- pyrazinamide 
Exposure variables OR [95% CI], p-value 
Regimen    
 [H]RfZE p=0.42 
 [H]RfZE-Fq/M 0.57 [0.14-2.28] 
Thrice weekly dosing  
 More frequent p=0.26 
 Thrice weekly 3.15 [0.43-23.11] 
Phenotype    
 Highly resistant p=0.78 
 Resistant 1.99 [0.10-37.81] 
 Borderline, sensitive or results not logged 2.56 [0.14-47.85] 
Genotype    
 fabG1 C-15T p=0.31 
 katG S315T/N 2.06 [0.48-8.83] 
 Multiple/other * 
 
 
 
  
 Supplementary File 8 
In order to assess the impact of any documented treatment non-adherence on the regimen-
outcomes relationship, thrice weekly treatment was swapped for an adherence variable 
within the multivariable model. Evidence for effect modification between regimen and 
adherence was not detected. The inclusion of this variable did not have an appreciable 
impact on the effect estimate for treatment regimen (0.90 [0.50-1.63], 0.73; Supplementary 
File 8 Table 1). When individuals with any drug resistance pattern were included in the 
model the effect estimate also remained largely unaltered (0.98 [0.55-1.76], 0.94; 
Supplementary File 8 Table 2). 
 
After finding a potential association between drug resistance and site of disease with the use 
of Fqs (Supplementary File 4 Table 2), post hoc these variables were also included the main 
multivariable model. No discernible difference in the odds of a negative outcome between 
the two regimens was detected (0.96 [0.51-1.83], 0.91). 
 
Table 1: Sensitivity analysis- multivariable logistic regression of treatment regimen as 
a predictor of negative outcomes (adherence included) 
Multivariable logistic regression of treatment regimen as a predictor of negative regimen-specific 
outcomes in patients without additional drug resistance, unless to streptomycin, adjusted for all 
variables in the table. Sensitivity analysis adjusting for adherence to treatment instead of thrice 
weekly dosing. Model contains 453 patients. CI- confidence interval, E- ethambutol, Fq- 
fluoroquinolones, H- isoniazid, m- months, M- moxifloxacin, OR- odds ratio, p- p-value, Rf- rifamycin, 
TB- tuberculosis, Z- pyrazinamide 
Exposure variables OR [95% CI], p-value 
Regimen    
 [H]RfZE p=0.73 
 [H]RfZE-Fq/M 0.90 [0.50-1.63] 
Adherence issues or treatment gaps  
 No or unknown p=0.22 
 Not severe or of unknown severity 2.02 [0.90-4.52] 
 Severe 0.82 [0.31-2.17] 
Phenotype    
 Highly resistant p=0.32 
 Resistant 0.62 [0.17-2.28] 
 Borderline, sensitive or results not logged 2.01 [0.71-5.68] 
 Missing  
Sex   p=0.14 
 Male 1.52 [0.87-2.65] 
 Female  
Age (years)  
 18-37 1.08 [0.71-1.66] 
 Per 20 year increase  
Ethnic group  
 White 0.38 [0.14-1.00] 
 Black African 0.34 [0.09-1.36] 
 Black Other 0.52 [0.23-1.19] 
 Indian subcontinent 1.02 [0.42-2.48] 
 Other  
Previous TB diagnosis  
 No 2.70 [0.67-10.78] 
  Yes p=0.73 
  
 Table 2: Sensitivity analysis- multivariable logistic regression of treatment regimen as 
a predictor of negative outcomes (all patterns of drug resistance included) 
Multivariable logistic regression of treatment regimen as a predictor of negative regimen-specific 
outcomes, adjusted for all variables in the table (including the presence of additional drug resistance). 
Sensitivity analysis including all individuals, regardless of drug resistance status. Model contains 459 
patients. CI- confidence interval, E- ethambutol, Fq- fluoroquinolones, H- isoniazid, m- months, M- 
moxifloxacin, OR- odds ratio, p- p-value, Rf- rifamycin, TB- tuberculosis, Z- pyrazinamide 
Exposure variables OR [95% CI], p-value 
Regimen    
 [H]RfZE p=0.94 
 [H]RfZE-Fq/M 0.98 [0.55-1.76] 
Thrice weekly dosing  
 More frequent p=0.01 
 Thrice weekly 3.09 [1.31-7.33] 
Phenotype    
 Highly resistant p=0.68 
 Resistant 0.62 [0.19-2.02] 
 Borderline, sensitive or results not logged 1.17 [0.39-3.49] 
Sex    
 Male p=0.00 
 Female 2.25 [1.28-3.95] 
Age (years)    
 18-37 p=0.71 
 Per 20 year increase 1.09 [0.70-1.69] 
Ethnic group  
 White p=0.08 
 Black African 0.36 [0.13-0.97] 
 Black Other 0.32 [0.09-1.17] 
 Indian subcontinent 0.57 [0.24-1.35] 
 Other 0.99 [0.39-2.52] 
Previous TB diagnosis  
 No p=0.03 
 Yes 4.54 [1.22-16.83] 
Any additional drug resistance  
 Absent p=0.59 
  Present 1.19 [0.64-2.21] 
 
 
